Considering the differences in the tumor-reactive Pmel-1 frequency in the lymphoid and tumor tissues, there being no difference in the therapeutic effect between the TBI and TBI/IL-2 groups was contradictory (Figure 1B,C). This evidence concerns the gene IL2 and neoplasm.